TRAD CHI MED: ANNOUNCEMENT OF ANNUAL RESULTSFOR THE YEAR ENDED 31 DECEMBER 2024AND APPOINTMENT OF VICE PRESIDENT

TRAD CHI MED Holdings reported a revenue of 16.51 billion yuan for the fiscal year 2024, a year-on-year decrease of 8.9%; the net profit for the year was 20.771 million yuan, a significant year-on-year decrease of 98.5%. The company plans to distribute a final dividend of 0.35 HK cents per share, totaling a dividend of 8.65 HK cents for the year.In terms of business sectors, the revenue from pharmaceutical formulations was 6.97 billion yuan, a year-on-year decrease of 23.5%; the revenue from Traditional Chinese Medicine formula granules was 4.55 billion yuan, a year-on-year increase of 14.0%; the revenue from Chinese medicinal slices was 3.31 billion yuan, a year-on-year increase of 17.9%; and the revenue from the Traditional Chinese Medicine health industry was...Show More

TRAD CHI MED Holdings reported a revenue of 16.51 billion yuan for the fiscal year 2024, a year-on-year decrease of 8.9%; the net profit for the year was 20.771 million yuan, a significant year-on-year decrease of 98.5%. The company plans to distribute a final dividend of 0.35 HK cents per share, totaling a dividend of 8.65 HK cents for the year.In terms of business sectors, the revenue from pharmaceutical formulations was 6.97 billion yuan, a year-on-year decrease of 23.5%; the revenue from Traditional Chinese Medicine formula granules was 4.55 billion yuan, a year-on-year increase of 14.0%; the revenue from Chinese medicinal slices was 3.31 billion yuan, a year-on-year increase of 17.9%; and the revenue from the Traditional Chinese Medicine health industry was 1.39 billion yuan, a year-on-year decrease of 25.3%. The gross margin during the period was 47.6%, a decrease of 3.6 percentage points compared to the same period last year.The company continues to promote research and development innovation, with an annual R&D investment of 1.06 billion yuan. As of the end of 2024, the company has 22 R&D platforms with a total of 165 projects under research, 97 of which are Innovative Drugs projects. In addition, the company has established 16 Intelligent Manufacturing demonstration factories and continues to advance digital transformation and upgrades.